

OncoDEEP



MATERIAL


1 block or 20 slides (5µm on super Frost+)

Next-generation sequencing

- 313 genes, hotspots and CDS
- Depth of coverage at a median of 1000x
- Gene fusion panel for NSCLC

Cancer type specific package

- IHCs for targeted therapies
- IHCs for chemotherapies
- Other (translocation analysis, methylation)
- Unique combination of 5 biomarkers for immunotherapy



SOLID BIOPSY

INTEGRATED THERANOSTIC REPORT

- Molecular characterization of the tumor
- Treatment options for targeted therapies, chemotherapies and immunotherapies
- Clinical trials availability

RECOMMENDED FOR

- Every solid tumor (Stage III or IV) in adults
- Glioblastoma in children

OncoSTRAT&GO



MATERIAL


- 1 block or 25 slides (5µm on super Frost+)
- 2 blood samples (2 Streck tubes of 10 ml each)

Next-generation sequencing

- 313 genes, hotspots and CDS
- More than 350 gene fusions (translocations analyses)
- Depth of coverage at a median of 1000x
- Selection of up to 15 variants for potential further OncoTRACE analyses

Cancer type specific package

- IHCs for targeted therapies
- IHCs for chemotherapies
- Other (unusual splicing, methylation)
- Unique combination of 5 biomarkers for immunotherapy



SOLID BIOPSY

LIQUID BIOPSY

Next-generation sequencing

- 40 genes associated with mutations (SNV, Indel and CNV) of resistance and sensitivity to targeted therapies

INTEGRATED THERANOSTIC REPORT

- Molecular characterization of the tumor
- Treatment options for targeted therapies, chemotherapies and immunotherapies
- Clinical trials availability

RECOMMENDED FOR

Stage IV, metastatic cancers of the following type: Non Small Cell Lung Cancer; Breast Cancer (HR+ or HER2+); Colorectal Cancer; Prostate Cancer; CUP (cancer of unknown primary)

OncoSELECT



MATERIAL

2 blood samples (2 Streck tubes of 10 ml each)

Next-generation sequencing

- Analysis of more than 100 mutations of resistance and sensitivity to approved targeted therapies (SNV, Indel, translocation and CNV)

Specific genes selected for each cancer type:

- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Breast Cancer (HR+ & HER2+)

LIQUID BIOPSY

INTEGRATED THERANOSTIC REPORT


- Liquid biopsy view
- Reporting of variant(s) associated with resistance and/or new treatment options
- Treatment options for approved targeted therapies

RECOMMENDED FOR

Metastatic cancers of the following type:

- Non Small Cell Lung Cancer
- Breast Cancer (HR+ or HER2+)
- Colorectal Cancer

OncoTRACE



MATERIAL

2 blood samples (2 Streck tubes of 10 ml each)

Next-generation sequencing

- Each test is designed on the unique molecular signature of your tumor, coming from a previous genomic sequencing done through a solid or liquid biopsy analysis

Targets more individual-specific mutations (12) leading to a higher probability of ctDNA detection to monitor recurrence

- In addition 40 genes associated with mutations (SNV, Indel and CNV) of resistance and sensitivity to targeted therapies

LIQUID BIOPSY

INTEGRATED THERANOSTIC REPORT


















- Liquid biopsy view
- Dynamic evolution of the personalized variants
- Reporting of new variant(s) associated with resistance and/or new treatment options
- Treatment options for targeted therapies
- Clinical trials availability






RECOMMENDED FOR

Any stage IV metastatic tumour type with an established genomic profile






Which analysis to choose for your patient?

	 OncoDEEP	 OncoSTRAT&GO	 OncoSELECT
Stage I or II			
Stage III			
Stage IV for <u>OTHER THAN</u> : NSCLC, Colon, Breast (HR+ or HER2+), CUP, Prostate			
Stage IV for : NSCLC, Colon, Breast (HR+ or HER2+), CUP, Prostate			
Stage IV for : NSCLC, Colon, Breast (HR+ or HER2+)	No SOLID biopsy available 		

	 OncoTRACE
Stage I or II	
Stage III	
From OncoSTRAT&GO results	
From any previous sequencing results with a minimum of genes (+/- 100)	

OncoTRACE can be used **ONLY** if a previous sequencing has been performed with a panel of genes that will allow us to monitor at least 10 variants. Usually a panel of min 100 genes is enough.

 : Recommended	 : Accepted	 : Strongly discouraged
---	--	--

